In the eye of innovation, timing is everything, and DefEYE, Inc. just locked in perfect vision. The Sarasota-based ophthalmic biologics company announced a strategic investment from ExSight Ventures, one of the sharpest VCs in eye care. The amount stays under wraps, but let’s be real, this is precision capital, fueling a $12M Series Seed Preferred Equity round already turning heads across biotech. That round included an in-kind investment from Celularity Inc. (Nasdaq: CELU), a regenerative medicine powerhouse that now stands as DefEYE’s exclusive manufacturing partner. When science meets scalability, the results don’t just look good, they heal.
DefEYE isn’t a startup built on hype; it’s evolution in motion. Formed in 2025 out of Verséa Ophthalmics, the company came ready with commercial traction, clinical validation, and leadership that’s been there, done that, and built the future while doing it. At the helm is Dr. Rob Sambursky, a Wills Eye Hospital-trained corneal specialist and serial entrepreneur whose fingerprints are all over the modern ophthalmic playbook. From founding RPS Diagnostics, later merging into Lumos Diagnostics, to creating Visus Therapeutics, Dr. Sambursky has a record of turning ideas into impact. His mix of clinical precision and entrepreneurial instinct gives DefEYE the rare blend of science and swagger this market rarely sees.
Backing him is Robert Glashow, CFO and financial tactician with $500M+ raised across multiple IPOs and SPACs. Together, they’re scaling DefEYE’s biologics engine with surgical accuracy. Their core: decellularized placental-based tissue solutions that regenerate rather than replace. Products like Biovance & Biovance 3L Ocular, single and tri-layer amniotic membranes, set a new bar for treating ocular surface disease and surgical repair. Add Interfyl, a flowable connective tissue matrix, and CentaFlex, a placental matrix for soft-tissue repair, and you’ve got a regenerative trifecta engineered for outcomes that feel borderline evolutionary.
Celularity’s exclusive license and pricing deal gives DefEYE the muscle to manufacture at scale without losing clinical integrity, a strategic move that transforms capability into dominance. And ExSight Ventures saw the signal early. Led by Dr. Firas Rahhal, Dr. Michael Nissen, and James Murray, JD, ExSight dug deep through its ophthalmology network. The feedback was crystal clear: better outcomes, faster recovery, happier patients. Skepticism turned to conviction.
With sales growth up nearly 70% in 2024, DefEYE isn’t chasing trends, it’s building momentum. This is what happens when foresight meets focus. The company isn’t just seeing the future of eye care, it’s shaping it, one decellularized breakthrough at a time.
